

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer

NCT06244537

Status	RECRUITING
Phase	Not Applicable
Sponsor	Sichuan Cancer Hospital and Research Institute
Enrollment	20 participants

Plain Language Summary

This study is testing MR-Linac — a cutting-edge radiation therapy machine that combines an MRI scanner with a radiation delivery system, allowing highly precise, real-time imaging during treatment — in patients with colon cancer that is locally advanced and cannot be surgically removed.

****You may be eligible if...****

- You are over 18 years old
- You have been diagnosed with colon adenocarcinoma (a specific type of colon cancer) that is locally advanced (stage T4) but has not spread to distant organs
- You can lie still for 1 to 1.5 hours during each treatment session
- Your general health score is 0 or 1 (you can perform most daily activities)
- Your blood counts and organ function tests are within acceptable ranges

****You may NOT be eligible if...****

- Your tumor has the MSI-H or dMMR genetic feature (these cancers often respond better to immunotherapy)
- You have another type of cancer in addition to colon adenocarcinoma
- You have a metal implant or other contraindication to MRI
- You are pregnant or breastfeeding

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (7)

- Patients over 18 years old
- Patients can remain in a stationary position on the treatment bed for 1-1.5 hours
- ECOG score 0-1
- Pathological diagnosis of colon adenocarcinoma, clinical stage cT4N0-2M0
- Organ function is normal, and the following conditions are required: white blood cell count $\geq 3.5 \times 10^9/L$; platelet count $\geq 100 \times 10^9/L$; hemoglobin $\geq 90g/L$. Total bilirubin level $\leq 1.5 \times$ upper limit of normal (ULN); AST and ALT levels $\leq 2.5 \times$ ULN; endogenous creatinine clearance rate: 56-122ml/min; serum creatinine $\leq 1.0 \times$ ULN; serum albumin $\geq 30g/L$.

... and 2 more (see full listing online)

Exclusion (12)

- Patients with dMMR or MSI-H
- Presence of other types of tumors in addition to colon adenocarcinoma
- Claustrophobia or inability to undergo MRI or treatment due to the presence of metal implants or other reasons
- Distant metastasis (M1)

• Pregnant or lactating women
<https://clinicaltrials.gov/study/NCT06244537>
and 7 more (see full listing online)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.

Locations (1 total)

Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China.,
Chengdu, Sichuan, China